RT Journal Article
SR Electronic
T1 Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 phase 3 study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.01.20087668
DO 10.1101/2020.05.01.20087668
A1 Guenther, Michael
A1 Haas, Michael
A1 Heinemann, Volker
A1 Kruger, Stephan
A1 Westphalen, Christoph Benedikt
A1 von Bergwelt-Baildon, Michael
A1 Mayerle, Julia
A1 Werner, Jens
A1 Kirchner, Thomas
A1 Boeck, Stefan
A1 Ormanns, Steffen
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087668.abstract
AB Background Gram-negative bacteria mediated gemcitabine resistance in pre-clinical models. We determined if intratumoral lipopolysaccharide (LPS) detection by immunohistochemistry is associated with outcome in advanced pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine and non-gemcitabine containing 1st-line chemotherapy.Methods We examined LPS on tumor tissue from 130 patients treated within the randomized phase 3 trial AIO-PK0104 and a validation cohort (n=113) from a prospective biomarker study and analyzed the association of LPS detection to patient outcome according to treatment subgroups.Results In 24% of samples from the AIO-PK0104 study LPS was detected; in LPS-positive patients median OS was 4.4 months, compared to 7.3 months with LPS negative tumors (HR 1.732, p=0.010). A difference in OS was detected in the subgroup of patients treated with 1st-line gemcitabine-based treatment (n=71; HR 2.377, p=0.002), whereas no difference in OS was observed in the non-gemcitabine subgroup (n=59; HR 1.275, p=0.478). Within the validation cohort, the LPS positivity rate was 23%, and LPS detection was correlated with impaired OS in the gemcitabine subgroup (n=94; HR 1.993, p=0.008) whereas no difference in OS was observed in the non-gemcitabine subgroup (n=19; HR 2.596, p=0.219).Conclusions The detection of intratumoral LPS as a surrogate marker for gram-negative bacterial colonization may serve as a negative predictor for gemcitabine efficacy in advanced PDAC.Clinical trial registry NCT00440167Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00440167Funding StatementThis study was financed by internal funds of the Institute of Pathology, LMU.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall supplemental data can be obtained upon request